Product
Supplier
Encyclopedia
Inquiry
Home > Chemical Reagents > Organic Reagents > Relugolix for Sale > Relugolix737789-87-6C29H27F2N7O5S
Relugolix737789-87-6C29H27F2N7O5S buy - large image1
Relugolix737789-87-6C29H27F2N7O5S buy - image1
Relugolix737789-87-6C29H27F2N7O5S buy - image2
Relugolix737789-87-6C29H27F2N7O5S buy - image3
Relugolix737789-87-6C29H27F2N7O5S buy - image4
Relugolix737789-87-6C29H27F2N7O5S buy - image5
Relugolix737789-87-6C29H27F2N7O5S buy - image6

Relugolix737789-87-6C29H27F2N7O5S

7 Inquiries

Unit Price:

$33-34/MT FOB

Get Latest Price
CAS No.:

737789-87-6

Grade:

Pharmaceutical Grade

Content:

99.5%

Port:

shanghai

Brand:

OORENT

Packaging:

Vial/Bottle/Bag/Carton

Sample Available:

Yes

Price valid (until):

2026-12-04

Company Type:
Trader
Location:
China
Payment Terms:
100% TT in advance
Average Lead Time:
10 days
Qualification:
Main Products:

pharmaceutical intermediates,peptides,electronic chemicals

  • Product Details

  • Seller Information

  • Inquiry History

  • Description

    Product Detailv


    Relugolix Basic information
    Product Name: Relugolix
    Synonyms: Relugolix;Altropane;TKA-385 Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;Relugolix TAK-385;TAK-385,Relugolix;CS-2851;TAK-385;TAK 385;TAK385
    CAS: 737789-87-6
    MF: C29H27F2N7O5S
    MW: 623.63
    EINECS: 237-099-7
    Product Categories: API;737789-87-6
    Mol File: 737789-87-6.mol
    Shop Relugolix737789-87-6C29H27F2N7O5S-Detailed Image 1

    Relugolix Chemical Properties
    Melting point  228 °C (decomp)(Solv: ethyl acetate (141-78-6); tetrahydrofuran (109-99-9))
    density  1.442±0.06 g/cm3(Predicted)
    storage temp.  Store at -20°C
    solubility  DMSO:20.0(Max Conc. mg/mL);32.1(Max Conc. mM)
    Ethanol:1.0(Max Conc. mg/mL);1.6(Max Conc. mM)
    form  A crystalline solid
    pka 13.17±0.70(Predicted)
    color  White to off-white
    InChIKey AOMXMOCNKJTRQP-UHFFFAOYSA-N
    SMILES N(C1=CC=C(C2SC3=C(C=2CN(C)C)C(=O)N(C2=NN=C(OC)C=C2)C(=O)N3CC2=C(F)C=CC=C2F)C=C1)C(NOC)=O

    Safety Information
    MSDS Information


    Relugolix Usage And Synthesis
    Description Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. It possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.
    Uses Relugolix is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment
    Mechanism of action The mechanism of action of relugolix is as a Gonadotropin Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion.
    Pharmacokinetics Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.12 nM).A single oral administration of relugolix at a dose of 3 mg/kg has been found to suppress luteinizing hormone (LH) levels for more than 24 hours in castrated cynomolgus monkeys, indicating a long duration of action. The drug (80–160 mg/day) has been found to reduce testosterone levels to sustained castrate levels in men with once-daily administration.[8] Lower dosages (10–40 mg/day) are being studied in the treatment of endometriosis and uterine fibroids to achieve partial sex hormone suppression.  The reasoning behind partial suppression for these conditions is to reduce the incidence and severity of menopausal symptoms such as hot flushes and to avoid bone mineral density changes caused by estrogen deficiency that can eventually lead to osteoporosis.
    Clinical Use Relugolix was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. Relugolix has also been studied in the symptomatic treatment of endometriosis. 
    Side effects Common side effects of Relugolix include: hot flashes; flushing of the skin; sweating; weight gain or loss of ability; pain in the muscles, back, joints or bones; fatigue; diarrhoea; constipation; difficulty sleeping; depression; and breast enlargement. More serious side effects include: dizziness; fainting; rapid heartbeat; or chest pain; swelling of the face, lips, mouth or tongue; difficulty breathing or swallowing; rash; measles; redness of the skin; chest pain or tightness in the chest; or pain in the arms, back, neck or jaw; sudden numbness or weakness of the face, arms, or legs (especially on one side of the body); sudden blurred consciousness; difficulty speaking or understanding; sudden difficulty seeing with one or both eyes; or sudden difficulty walking, walking, or seeing with one or both eyes. or sudden difficulty walking, dizziness, loss of balance or coordination, etc.
    Synthesis Relugolix is produced by the reaction of 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione and phenyl N-methoxycarbamate.Shop Relugolix737789-87-6C29H27F2N7O5S-Detailed Image 2


    Shop Tirzepatide2023788-19-2-Detailed Image 2 Shop Tirzepatide2023788-19-2-Detailed Image 3 Shop Tirzepatide2023788-19-2-Detailed Image 4 Shop Tirzepatide2023788-19-2-Detailed Image 5 Shop Tirzepatide2023788-19-2-Detailed Image 6 Shop Tirzepatide2023788-19-2-Detailed Image 7

     

    ECHEMI Editorial Reference
    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer.|Relugolix is a Gonadotropin Releasing Hormone Receptor Antagonist. The mechanism of action of relugolix is as a Gonadotropin Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion.|Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
    Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. It possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.

    Basic Info
    Product Name:

    Relugolix

    Other Name:

    Relugolix;Altropane;TKA-385 Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;Relugolix TAK-385;TAK-385,Relugolix;CS-2851;TAK-385;TAK 385;TAK385

    CAS No.:

    737789-87-6

    Molecular Formula:

    C29H27F2N7O5S

    InChIKeys:

    AOMXMOCNKJTRQP-UHFFFAOYSA-N

    Molecular Weight:

    623.63

    Exact Mass:

    623.63

    EC Number:

    237-099-7

    UNII:

    P76B05O5V6

    DSSTox ID:

    DTXSID40224167

    NCI Thesaurus Code:

    C114498

    Color/Form:

    White to off-white

    ATC Code:

    H01CC54

    Categories:

    Organic Reagents

    Characteristics
    Density:

    1.442±0.06 g/cm3(Predicted)

    Melting Point:

    228 °C (decomp)(Solv: ethyl acetate (141-78-6); tetrahydrofuran (109-99-9))

    PKA:

    13.17±0.70(Predicted)

    Critical Temperature & Pressure:

    Store at -20°C

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    pharmaceutical intermediates,peptides,electronic chemicals

    Location:

    Room 102, 1st Floor, East Office Building, No. 45 Pengwan Road, Qianwan Bonded Port Area, Qingdao Zone, China (Shandong) Pilot Free Trade Zone

    Payment Terms:

    100% TT in advance

    Average lead Time:

    10 days

    Total Annual Revenue:

    $10 million-$25 million

    Total Employees:

    51-100

    Year of Establishment:

    2024

    A reliable supplier is like insurance.

    We are mainly specilized in supply of pharmaceutical intermediates, electronic chemicals,food additives, and other fine chemical products.
    Integrity is the foundation, quality is life. We would like to work together with you to build a greener and brighter future.

    Website: orientchem.cc
    Email: scarlett@orientchem.cc
    WhatsApp: +86 17753254221

  • Inquiry History
    7 Inquiries
    Country Product Purchase Quantity Date Posted
    United Kingdom

    Relugolix

    1.00 KG Nov 3, 2026
    United Kingdom

    Ascorbic Acid

    1.00 KG Sep 10, 2026
    Bangladesh

    RELUGOLIX

    1 20' Fcl Dec 12, 2025
    United States

    99% Pharmacy Grade Relugolix

    100 G Nov 30, 2025
    Greece

    Relugolix tablets

    120 MG Nov 14, 2025
    Greece

    Relugolix tablets

    120 MG Nov 14, 2025
    United States

    Relugolix

    10 G Sep 15, 2025
    Post an enquiry for this product

More from this Seller

pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.